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Purpose: To evaluate the effect of antiepileptic drugs (AEDs) on cognition and behavior in 
adult epileptic males controlled on treatment with conventional antiepileptic medications.
Methods: Cognitive, mood, behavior and personality traits were assessed in 45 epileptic 
patients treated with carbamazepine and/or valproate and free of seizures for 1 year. Thirty-
four newly diagnosed or untreated patients with epilepsy and 58 matched healthy subjects were 
also included for comparison. A battery of psychometric tests was utilized including Stanford-
Binet (4th edition), Beck Inventory for Depression, Aggressive Scale and Eysenck Personality 
Questionnaire.
Results: Compared to matched control subjects, treated and untreated epileptic patients had 
poor performance in different cognitive and behavioral functions testing. Treated patients had 
worse scores in memory for digits forward and backward, total short-term memory, extrover-
sion and psychosis. The duration of AEDs intake was correlated with memory of objects 
(r = -0.323; P = 0.030), bead memory (r = -0.314; P = 0.036) and total nonverbal short-term 
memory (r = -0.346; P = 0.020). Treated and untreated epileptic patients had poor performance 
of similar extent in behavioral functions testing (depression, aggression and neurosis). The dose 
of AEDs was correlated with testing scores for neurosis (r = 0.307; P = 0.040), verbal aggression 
(r = 0.483; P = 0.001) and nonverbal aggression (r = 0.526; P = 0.000), and duration of drug 
intake was correlated with scores for depression (r = 0.384; P = 0.009), psychosis (r = 0.586; 
P = 0.0001) and nonverbal aggression (r = 0.300; P = 0.045).
Conclusions: This study provides support for the notion that AEDs can impair performance in 
cognition, mood and behavior. Duration of drug intake and the number of the utilized AEDs are 
the main confounding variables. This study did not provide clues on how to exclude the effect 
of epilepsy itself and psychosocial variables as additional important confounding variables.
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Introduction
Epilepsy is a common health problem.1 Seizures are only one aspect of epilepsy. Patients 
with epilepsy may experience cognitive and behavioral problems that may have a 
deleterious impact on patients’ overall lives.2,3 Cognitive comorbidity associated with 
epilepsy has been confirmed in clinical, experimental, pathological, psychological, 
physiological and imaging studies.4–6 Epileptic patients may experience problems 
in various cognitive domains such as reduced intelligence, attention, problems in 
memory, language and frontal executive functions, despite the side or site of lesion. 
The association between epilepsy and poor cognitive performance, learning and long-
term memory is correlated with a number of variables including genetics, basic brain 
lesion, site and side of structural brain lesion, and age at onset together with duration of Neuropsychiatric Disease and Treatment 2009:5 528
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epilepsy, seizure frequency, adverse effects from antiepileptic 
medications and psychosocial variables.7–10
Antiepileptic drugs (AEDs) have both negative and 
positive effects on cognition and behavior.5 AEDs are 
able to improve cognition and behavior, which has been 
attributed to reduction of seizure activity, and modulating 
effect on neurotransmitters and their psychotrophic effect. 
AEDs reduce neuronal irritability and increase postsynaptic 
inhibition or alter synchronization of neural networks to 
decrease excessive neuronal excitability associated with 
seizure development and secondary spread of epileptic 
activity to the surrounding normal brain. However, excessive 
reduction of neuronal excitability may result in slowed motor 
and psychomotor speeds, and poor attention and memory 
processing, which are common side effects of sodium channel 
blockade and increasing GABAergic inhibitory activity.11–13 
It is not surprising that patients with epilepsy are more 
susceptible to the adverse behavioral effects of AEDs than 
other populations, possibly due to the disease associated 
structural or functional changes that increase their risk of 
psychiatric disorders.
Aim of the work
This study aimed to evaluate the effect of conventional AEDs 
(carbamazepine [CBZ] and/or valproate [VPA]) on cognitive 
and behavioral functions in a group of adult epileptic males 
with generalized tonic–clonic convulsions and controlled 
(seizure free for 1 year) on AEDs. Correlations between 
cognitive and behavioral functions and variables related to 
AEDs (dose, duration of treatment and number of utilized 
AEDs) were also determined.
Patients and methods
This study included 79 consecutive patients (range 18 to 45) 
with generalized tonic–clonic convulsions (grand mal 
epilepsy) recruited from the outpatient epilepsy clinic 
of Assuit University Hospital, Assuit, Egypt. Epilepsy 
type was defined according to the International League 
Against Epilepsy (1989).14 The protocol of the study was 
in conformity with ethical guidelines of Assiut University 
Hospital, Egypt and informed written consent was obtained 
from each participant. Included in this study were: a) newly 
diagnosed and untreated epileptic patients: these were 
patients with at least one seizure during the last 6 months 
and who had not received AEDs (n = 34); b) treated 
epileptic patients: these were patients on regular treatment 
with one (monotherapy) or combined (polytherapy) AEDs 
(total: n = 45; CBZ: n = 25; VPA; n = 13; CBZ + VPA: n = 7). 
AEDs were described according to the well-known guidelines 
and in recommended doses. All treated patients gave a his-
tory of compliance to AEDs. Compliance was confirmed 
by assessment of the serum drug level at least once during 
the period of the study. The serum levels of AEDs were 
determined in the therapeutic drug monitoring lab, Assiut 
University Hospital, Assiut Egypt, with the fluorescence 
polarization immunoassay system of Abbott (EPIA) using 
TD × FLX apparatus (Abbott Lab, Wiesbaden, Germany), 
as described before.15 This study included 58 healthy 
males matched for age, sex, educational level and socio-
economic status as controls (Table1). Excluded from this 
study were a) patients with intelligence quotient (IQ) less 
than 70 assessed using Wechsler Adults Intelligence Scale-
Revised;16 b) presence of history of head injury; c) patients 
with progressive central nervous system (CNS), psychiatric 
or systemic medical conditions that might affect cognitive 
or behavioral functions; and d) patients utilizing chronic 
medications other than AEDs. The demographic and clini-
cal characteristics of the studied groups are summarized in 
Table 1.
All participants were subjected to:
1.  Complete neurological, medical history and examination, 
and socioeconomic status scale assessment.17
2.  Analysis of seizure history included: age at onset, dura-
tion of epilepsy, type and duration of AED(s) utilized and 
the degree patients’ control on AED(s). Only controlled 
patients on AEDs (seizure free for 1 year) were included 
in this study.
3.  Neuropsychological assessment
(a) Assessment of cognition
  Cognition was assessed using the standardized and 
validated Arabic version of the Stanford-Binet Test 
(4th edition).18,19 The test consisted of 30 items ranging 
from the ability to touch one’s nose or ear when asked, to the 
ability to draw designs from memory and to define abstract 
concepts. The following items were tested and analyzed: 
total verbal reasoning, which was used to assess vocabu-
lary, comprehension, absurdities and verbal relations; 
total nonverbal short-term memory, which tested memory 
for objects and bead memory; and total verbal short-term 
memory, which was used to assess memory for digits 
(forward and backward) and memory for sentences.
  (b)  Behavioral assessment
  A standardized and validated Arabic versions of the 
Beck Depression Inventory,20,21 the Aggressive Behavior 
Scale (Verbal and Nonverbal)22,23 and Eysenck Personality 
Inventory24,25 were used for behavioral and emotional Neuropsychiatric Disease and Treatment 2009:5 529
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assessment. The Beck Depression Inventory is a 
21-question multiple-choice self-report inventory, one 
of the most widely used instruments for measuring the 
severity of depression. Its development marked a shift 
among health care professionals, who had until then viewed 
depression from a psychodynamic perspective, instead of 
it being rooted in the patient’s own thoughts. In its current 
version the questionnaire is designed for individuals aged 
13 and over, and is composed of items related to symp-
toms of depression such as hopelessness and irritability, 
cognitions such as guilt or feelings of being punished, as 
well as physical symptoms such as fatigue, weight loss, and 
lack of interest in sex. The Aggressive Behavior Scale is 
a 64-item scale with excellent reliability and validity. It is 
used to assess verbal (32 items) and nonverbal aggressions 
(32 items). It measures levels of self-esteem, disinhibited 
behavior, aggression against persons and animals, control 
of rage, and so on. The scoring for each item ranges from 
1 to 4. Higher scores indicate higher levels of aggres-
sion. Eysenck Personality Inventory assesses neurosis, 
psychosis, extroversion–introversion, and lying. Neurosis 
is marked by excessive anxiety or apprehension that is not 
restricted to specific situations or objects, unlike anxiety 
experienced in threatening situations. Psychosis is a tem-
porary mental state. A person experiences a psychotic 
state for a while, and then come out of it. Psychoticism 
focuses on the disturbances of such magnitude that there is 
personality disintegration and loss of contact with reality. 
Extraversion is marked by direction of attention and energy 
outward from the self. Lying is typically used to refer to 
deceptions in oral or written communication.
Procedure
Cognitive and behavioral assessment of the patients was 
done individually. Patients were divided into two smaller 
groups. The first subgroup completed the vocabulary, 
comprehension, absurdities, verbal relations, memory for 
objects, bead memory, memory for sentences, memory for 
digits forward, and memory for digits backward tests in 
that order. The second subgroup completed the same tests 
in reverse order. The aim of this counterbalance was to 
control the training variable in cognitive function. Behavioral 
assessment was completed in another session.
Statistical analysis
Descriptive statistics (mean, SD, and percentages) were 
calculated using the computer software package SPSS 
for Windows, Version 16. Results were analyzed using 
independent-sample t test that did not assume equal 
variances. One-way analysis of variance (ANOVA) was 
followed by a post hoc test (LSD). Correlation coefficients 
and multiple linear regression analysis were used to detect 
the impact of epilepsy and its treatment on cognition, mood, 
aggressive behavior, and personality traits. The significance 
level was set at a 0.05.
Results
Table 1 demonstrates the demographic and clinical charac-
teristics of the studied groups. Tables 2 and 3 demonstrate the 
effect of AEDs on various cognitive and behavioral functions. 
Compared to matched control subjects, treated and untreated 
epileptic patients had poor performance in different cognitive 
and behavioral functions testing. However, treated patients 
Table 1 Demographic and clinical characteristics of the studied groups
   Controls 
(n = 58)
Untreated 
(n = 34)
Treated 
(n = 45)
Age, years 30.45 ± 7.56 28.09 ± 8.99 28.80 ± 7.69
Socioeconomic status 10.20 ± 3.914 9.68 ± 3.96 9.53 ± 3.75
Number of years of education 9.03 ± 5.67 7.91 ± 4.33 9.04 ± 3.74
intelligent quotient 
P value
85.72 ± 15.79 78.24 ± 20.13 88.13 ± 20.46 
0.035
Duration of illness; years – 11.35 ± 7.65 10.07 ± 6.59
Family history of epilepsy – 5 (14.7%) 11 (24.4%)
history of febrile convulsions 2 (5.9%) 3 (6.7%)
Family history of cognitive decline – 1 (3%) 3 (6.8%)
Duration of drug intake, years – – 8.54 ± 6.52
AeDs dose, mg/day 
cBZ 
VPA
– –  
739.39 ± 289.33 
822.22 ± 298.14
Notes: Data are expressed as mean ± SD, number (%).
Significance: between untreated and treated groups.
Abbreviations:   AeD, antiepileptic drug; cBZ, carbamazepine;  VPA, valproate.Neuropsychiatric Disease and Treatment 2009:5 530
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had worse scores in memory for digits forward, memory 
for digits forward and backward, total short-term memory, 
extroversion and psychosis. Patients on VPA had worse scores 
in total aggression and verbal aggression scores compared 
to those on CBZ or combined treatment with CBZ.
In the treated group of patients, the dose of AEDs was 
significantly associated with testing scores for neurosis 
(r = 0.307; P = 0.040), verbal aggression (r = 0.483; P = 0.001), 
nonverbal aggression (r = 0.526; P = 0.000). The duration 
of AED intake was significantly associated with testing 
scores for memory of objects (r = -0.323;P = 0.030), bead 
memory (r = -0.314; P = 0.036), total nonverbal short-term 
memory (r = -0.346; P = 0.020), Beck Depression Inventory 
(r = 0.384; P = 0.009), psychosis (r = 0.586; P = 0.0001) and 
nonverbal aggression (r = 0.300; P = 0.045). The number of 
AEDs was significantly correlated with testing scores for 
absurdities (r = 0.336; P = 0.024) but not associated with 
other cognitive or behavioral functions.
Discussion
The potential for AEDs to adversely impact cognition and 
behavior is of significant concern as they are the major thera-
peutic modality for control of seizures. Even their modest 
effects can be of clinical significant and affect the patient’s 
quality of life.26 In this study, we compared the results of 
cognitive and behavioral functions testing of a group of adult 
male patients who were seizure free for 1 year on con-
ventional AEDs (CBZ and VPA), with a group of epileptic 
patients who were newly diagnosed or did not ever received 
AEDs and a group of matched healthy subjects.
Others and ourselves have reported that epilepsy adverse 
affects different cognitive and behavioral functions.3,6,9,10,27 
Not only ictal but also interictal (subclinical) discharges, 
which occur with paroxysmal focal or generalized epileptic 
activities, can disrupt cognitive encoding processes.28–30 
In addition, neuronal plasticity, reorganization, sprouting 
and impairment of cellular metabolism associated with the 
process of epileptogenesis are fundamental determinants for 
progressive cognitive deterioration in epilepsy.31,32
The results of this study indicate that patients on conven-
tional AEDs are at increased risk for cognitive dysfunction. 
In support, both treated and untreated epileptic patients had 
poor performance of a similar extent in different cognitive 
(as in scoring for absurdities, total verbal reasoning, memory 
for objects, bead memory and nonverbal short-term memory) 
and behavioral (as in scoring for depression, aggression and 
neurosis) functions testing. The effect of AEDs on cognition 
has been attributed to the fact that AEDs not only reduce 
neuronal irritability but also may impair neuronal excitability, 
neurotransmitter release, enzymes and factors critical for 
information processing and memory. Several previous studies 
indicated that AEDs have reversible and sometimes cumula-
tive cognitive adverse consequences.33,34 Treated patients 
demonstrated worse scores in memories for digits forward, 
backward, and total verbal short-term memory) compared to 
untreated epileptic patients. The duration of AED intake was 
found to be associated with memory of objects, bead memory 
and total nonverbal short-term memory. In this study, no sig-
nificant correlation was identified between cognitive functions 
and the dose of the AEDs. The number of utilized antiepileptic 
medications was significantly correlated with testing scores 
for absurdities.
In this study, no differential effect was identified between 
CBZ versus VPA therapy. CBZ utilization may be associated 
with mild cognitive dysfunction including excessive sedation, 
compromised attention, concentration and visual motor coor-
dination, and psychomotor slowing. EEG slowing associated 
with CBZ might be significantly related to the magnitude of 
cognitive decline on later IQ subset performance.35 Studies 
revealed that children exposed to VPA in utero had learning 
difficulties, behavioral problems and increased need for 
special education.36 In one large prospective study, increased 
memory deficits, reduced verbal IQ by 8 to 15 points and an 
excess of additional needs were reported in children exposed 
to VPA prenatally.37 The cognitive side effects of CBZ have 
been attributed to their Na+ channels blockade.38 VPA’s 
modest effect on cognition has been attributed to the indirect 
modulation of GABA neurotransmissions. An enhancement 
of GABAA receptor-mediated hyperpolarizing responses 
caused by VPA will inhibit the activation of NMDA receptors 
in a dose-related manner and VPA reduces repetitive neuronal 
firing via blockade of voltage-dependant sodium (Na+) 
channels.39,40 Its suppressive effect on synaptic response medi-
ated by NMDA receptors may contribute to the impairment 
of long-term potentiation (LTP) and long-term depression 
(LTD) caused by VPA. VPA suppresses the expression of 
LTP in the CA1 region of the hippocampal slices.41 VPA 
suppresses response mediated by NMDA receptors in a 
dose-related manner rat amygdaloid slices.42
The results of this study indicate that patients on 
conventional AEDs are at increased risk of behavioral 
abnormalities. In support, both treated and untreated epileptic 
patients had a similar extent of  poor performance in behavioral 
functions testing (as in scoring for depression, aggression and 
neurosis). The dose of AEDs was significantly associated with 
testing scores for neurosis, verbal aggression and nonverbal Neuropsychiatric Disease and Treatment 2009:5 531
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aggression, and the duration of AED intake was significantly 
associated with testing scores for depression, psychosis and 
nonverbal aggression. The relationship between AEDs and 
depression, aggression and neurosis in our group of patients 
could be attributed to psychosocial variables. The stigma 
resulting from epilepsy and learning problems may lower the 
parental and teacher expectations, scholastic achievement, 
educational levels rates of employment and hence poor 
quality of life, which are the long-term consequences in 
adults with epilepsy.43,44 But we cannot exclude the fact 
that depression, neurosis and psychosis in epilepsy might 
result from biological causes (epilepsy itself) in addition to 
reactive factors including AEDs. Functional neuroimaging 
studies (eg, PET and SPECT) have shown a relationship 
between heightened depression and hypometabolism in epi-
leptic patients.45 The risk of cognitive side effects should be 
reduced by using monotherapy whenever possible, staying 
within standard therapeutic ranges for AED blood levels, and 
adhering to recommended drug dosages and titration rates.31 
Neuropsychological side effects generally emerge according 
to a dose-dependent relationship.29 However, both quality 
of life35 and memory are affected, even when serum blood 
concentrations are within standard therapeutic ranges.
In summary, the results of this study provide a support for 
the notion that conventional AEDs are associated with poor 
performance in cognition, mood and behavior in patients with 
epilepsy. Duration of drug intake and the number of utilized 
AEDs are the main confounding variables. This study did 
not provide clues on how to exclude the effect of epilepsy 
itself and psychosocial variables as additional important 
confounding variables.
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